• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Life Sci Alliance . Clonal landscape of autoantibody-secreting plasmablasts in COVID-19 patients

tetano

Editor, Senior Moderator
Life Sci Alliance


. 2024 Sep 17;7(12):e202402774.
doi: 10.26508/lsa.202402774. Print 2024 Dec. Clonal landscape of autoantibody-secreting plasmablasts in COVID-19 patients

Shuhei Sakakibara[SUP] 1 [/SUP], Yu-Chen Liu[SUP] 2 [/SUP], Masakazu Ishikawa[SUP] 2 3 [/SUP], Ryuya Edahiro[SUP] 4 5 6 [/SUP], Yuya Shirai[SUP] 4 5 6 [/SUP], Soichiro Haruna[SUP] 7 [/SUP], Marwa Ali El Hussien[SUP] 7 [/SUP], Zichang Xu[SUP] 8 [/SUP], Songling Li[SUP] 8 [/SUP], Yuta Yamaguchi[SUP] 4 9 [/SUP], Teruaki Murakami[SUP] 4 9 [/SUP], Takayoshi Morita[SUP] 4 9 [/SUP], Yasuhiro Kato[SUP] 4 9 [/SUP], Haruhiko Hirata[SUP] 4 [/SUP], Yoshito Takeda[SUP] 4 [/SUP], Fuminori Sugihara[SUP] 10 [/SUP], Yoko Naito[SUP] 11 [/SUP], Daisuke Motooka[SUP] 2 11 12 [/SUP], Chao-Yuan Tsai[SUP] 7 [/SUP], Chikako Ono[SUP] 3 13 14 [/SUP], Yoshiharu Matsuura[SUP] 3 13 14 [/SUP], James B Wing[SUP] 3 15 14 [/SUP], Hisatake Matsumoto[SUP] 3 16 [/SUP], Hiroshi Ogura[SUP] 3 16 [/SUP], Masato Okada[SUP] 14 [/SUP], Atsushi Kumanogoh[SUP] 3 4 9 12 14 17 [/SUP], Yukinari Okada[SUP] 3 5 6 12 14 18 19 [/SUP], Daron M Standley[SUP] 3 8 14 [/SUP], Hitoshi Kikutani[SUP] 20 [/SUP], Daisuke Okuzaki[SUP] 2 3 11 12 17 [/SUP]



Affiliations
Free article Abstract

Whereas severe COVID-19 is often associated with elevated autoantibody titers, the underlying mechanism behind their generation has remained unclear. Here we report clonal composition and diversity of autoantibodies in humoral response to SARS-CoV-2. Immunoglobulin repertoire analysis and characterization of plasmablast-derived monoclonal antibodies uncovered clonal expansion of plasmablasts producing cardiolipin (CL)-reactive autoantibodies. Half of the expanded CL-reactive clones exhibited strong binding to SARS-CoV-2 antigens. One such clone, CoV1804, was reactive to both CL and viral nucleocapsid (N), and further showed anti-nucleolar activity in human cells. Notably, antibodies sharing genetic features with CoV1804 were identified in COVID-19 patient-derived immunoglobulins, thereby constituting a novel public antibody. These public autoantibodies had numerous mutations that unambiguously enhanced anti-N reactivity, when causing fluctuations in anti-CL reactivity along with the acquisition of additional self-reactivities, such as anti-nucleolar activity, in the progeny. Thus, potentially CL-reactive precursors may have developed multiple self-reactivities through clonal selection, expansion, and somatic hypermutation driven by viral antigens. Our results revealed the nature of autoantibody production during COVID-19 and provided novel insights into the origin of virus-induced autoantibodies.


 
Back
Top Bottom